Photo of Zhirui Wang,  PhD

Zhirui Wang, PhD

Massachusetts General Hospital

Massachusetts General Hospital
Phone: (617) 643-1957


zhirui.wang@tbrc.mgh.harvard.edu

Zhirui Wang, PhD

Massachusetts General Hospital

EDUCATIONAL TITLES

  • Assistant Professor, Surgery, Harvard Medical School
  • Assistant Immunologist, TBRC/Surgery , Massachusetts General Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

My main area of expertise involves the use of the yeast Pichia pastoris expression system as a platform for recombinant protein development. My research focuses primarily on the original design, efficient expression and improved function of novel recombinant immunotoxins for development of targeted recombinant protein drugs. Since 2008, I have served as the Technical Director of the DF/HCC-MGH Recombinant Protein Expression and Purification Core Facility responsible for the administrative, scientific, and educational activities of the core. Under my supervision, we have successfully completed more than 50 recombinant protein expression and purification projects for DF/HCC and MGH investigators. Of particular relevance to the cancer research, we have successfully developed species specific IL-2 fusion toxins (murine, human and porcine) effective for in vivo depletion of IL-2 receptor positive cells, including regulatory T cells. We have also developed anti-porcine CD3 immunotoxin for in vivo depletion of porcine CD3 cells and porcine CTLA-4 fusion toxin for in vivo depletion of porcine CD80/CD86 cells.

Publications

Powered by Harvard Catalyst
  • Peraino JS, Zhang H, Rajasekera PV, Wei M, Madsen JC, Sachs DH, Huang CA, Wang Z. Diphtheria toxin-based bivalent human IL-2 fusion toxin with improved efficacy for targeting human CD25(+) cells. J Immunol Methods 2014; 405:57-66. PubMed
  • Peraino JS, Schenk M, Li G, Zhang H, Farkash EA, Sachs DH, Huang CA, Duran-Struuck R, Wang Z. Development of a diphtheria toxin-based recombinant porcine IL-2 fusion toxin for depleting porcine CD25+ cells. J Immunol Methods 2013; 398-399:33-43. PubMed
  • Wamala I, Matar AJ, Farkash E, Wang Z, Huang CA, Sachs DH. Recombinant anti-monkey CD3 immunotoxin depletes peripheral lymph node T lymphocytes more effectively than rabbit anti-thymocyte globulin in na誰ve baboons. Transpl Immunol 2013; 29:60-3. PubMed
  • Peraino JS, Schenk M, Zhang H, Li G, Hermanrud CE, Neville DM, Sachs DH, Huang CA, Duran-Struuck R, Wang Z. A truncated diphtheria toxin based recombinant porcine CTLA-4 fusion toxin. J Immunol Methods 2013. PubMed
  • Matar AJ, Pathiraja V, Wang Z, Duran-Struuck R, Gusha A, Crepeau R, Tasaki M, Sachs DH, Huang CA. Effect of pre-existing anti-diphtheria toxin antibodies on T cell depletion levels following diphtheria toxin-based recombinant anti-monkey CD3 immunotoxin treatment. Transpl Immunol 2012; 27:52-4. PubMed
  • Hermanrud CE, Pathiraja V, Matar A, Duran-Struuck R, Crepeau RL, Srinivasan S, Sachs DH, Huang CA, Wang Z. Expression and purification of non-N-glycosylated porcine interleukin 3 in yeast Pichia pastoris. Protein Expr Purif 2012; 82:70-4. PubMed
  • Peraino J, Zhang H, Hermanrud CE, Li G, Sachs DH, Huang CA, Wang Z. Expression and purification of soluble porcine CTLA-4 in yeast Pichia pastoris. Protein Expr Purif 2012; 82:270-278. PubMed
  • Wang Z, Duran-Struuck R, Crepeau R, Matar A, Hanekamp I, Srinivasan S, Neville DM, Sachs DH, Huang CA. Development of a diphtheria toxin based antiporcine CD3 recombinant immunotoxin. Bioconjug Chem 2011; 22:2014-20. PubMed
  • Nishimura H, Scalea J, Wang Z, Shimizu A, Moran S, Gillon B, Sachs DH, Yamada K. First experience with the use of a recombinant CD3 immunotoxin as induction therapy in pig-to-primate xenotransplantation: the effect of T-cell depletion on outcome. Transplantation 2011; 92:641-7. PubMed
  • Hermanrud CE, Lucas CL, Sykes M, Huang CA, Wang Z. Expression and purification of soluble murine CD40L monomers and polymers in yeast Pichia pastoris. Protein Expr Purif 2010; 76:115-20. PubMed
  • Kim GB, Wang Z, Liu YY, Stavrou S, Mathias A, Goodwin KJ, Thomas JM, Neville DM. A fold-back single-chain diabody format enhances the bioactivity of an anti-monkey CD3 recombinant diphtheria toxin-based immunotoxin. Protein Eng. Des. Sel. 2007; 20:425-32. PubMed
  • Liu YY, Wang Z, Thomas J, Goodwin KJ, Stavrou S, Neville DM. Polymorphisms of CD3epsilon in cynomolgus and rhesus monkeys and their relevance to anti-CD3 antibodies and immunotoxins. Immunol Cell Biol 2007; 85:357-62. PubMed
  • Wang Z, Neville DM. Expression and characterization of recombinant soluble monkey CD3 molecules: mapping the FN18 polymorphic epitope. Mol Immunol 2004; 40:1179-88. PubMed
  • Woo JH, Liu YY, Mathias A, Stavrou S, Wang Z, Thompson J, Neville DM. Gene optimization is necessary to express a bivalent anti-human anti-T cell immunotoxin in Pichia pastoris. Protein Expr Purif 2002; 25:270-82. PubMed
  • Peraino JS, Hermanrud CE, Springett L, Zhang H, Li G, Srinivasan S, Gusha A, Sachs DH, Huang CA, Wang Z. Expression and characterization of recombinant soluble porcine CD3 ectodomain molecules: mapping the epitope of an anti-porcine CD3 monoclonal antibody 898H2-6-15. Cell Immunol 2012; 276:162-7. PubMed
  • Wang Z, Kim GB, Woo JH, Liu YY, Mathias A, Stavrou S, Neville DM. Improvement of a recombinant anti-monkey anti-CD3 diphtheria toxin based immunotoxin by yeast display affinity maturation of the scFv. Bioconjug Chem 2007; 18:947-55. PubMed
Hide